LUTS

Laborie Medical Technologies Invests in iO Urology and the CarePath Uroflow Device

Retrieved on: 
Friday, March 29, 2024
Urology, Disease, Education, Patient, LUTS, Malignancy, BPH, FDA, Pharmaceutical industry

PORTSMOUTH, N.H., March 29, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.

Key Points: 
  • PORTSMOUTH, N.H., March 29, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.
    CarePath's simplistic model allows the device to be shipped directly to the patient's home and uses embedded cellular connectivity.
  • With CarePath, 91% of patients returned to the clinic to review the CarePath Uroflow report with their provider and consider surgical intervention.
  • "The team at iO Urology developed a state-of-the-art device with a dynamic patient ecosystem that empowers patient engagement as a superior standard of care.
  • "We're eager to collaborate with Laborie, pioneers in diagnostic and therapeutic urologic healthcare," said iO Urology Co-Founder and CEO Britton Garrett.

2024 AUA Data Research Program Awardees Announced

Retrieved on: 
Tuesday, February 13, 2024
FACS, Patient, Census, Overactive bladder, MBA, Master of Philosophy, Registry, LUTS, Urology, Practice, Abstract, AUA, AQUA, Integration, Health policy, United, American Urological Association, Workforce, Publication, Research

BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to select six research teams as recipients of the 2024 AUA Data Research Program.

Key Points: 
  • BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to select six research teams as recipients of the 2024 AUA Data Research Program.
  • The AUA Data Research Program (formerly AUA Data Grants), launched in May 2023, supports two clinical and four workforce research projects annually using data from AUA Data Repositories to address key knowledge gaps and emerging research questions related to urological care, workforce development, and health policy.
  • Awardees will use real-world clinical data from the AUA Quality (AQUA) Registry and population representative AUA Annual Census data to conduct clinical and workforce studies.
  • “In conceptualizing the AUA Data Research Program, we realize that there are many AUA members with outstanding research ideas but who may lack the resources to pursue these critical questions,” said Dr. Hung-Jui (Ray) Tan, Chair of the AUA Data Research Program.

American Urological Association Names New Research Chair

Retrieved on: 
Thursday, January 11, 2024
Male, American Urological Association, Weill Cornell Medicine, Interstitial cystitis, MD, CPP, LUTS, Baylor College of Medicine, Baylor University, Chair, Signs and symptoms, NIH, AUA, Bangladesh Technical Education Board, The, Anesthesiology, Education, Management

BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of Medicine, as the new Chair of the AUA Office of Research.

Key Points: 
  • BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of Medicine, as the new Chair of the AUA Office of Research.
  • As Research Chair, Dr. Lai will lead the research components of the AUA and Urology Care Foundation missions, focusing on implementing strategic goals.
  • The main objective is to advance research in urologic diseases by engaging with the AUA Research Council and collaborating closely with the AUA Director of Research.
  • Specifically, the Chair partners with the AUA Office of Research and urologic research stakeholders to ensure the future of urology surgeon-scientists, enhance strategic programming in research funding and education, and support AUA research advocacy in public and private sectors.

Bright Uro Announces $23M Series A Funding Round Led by Laborie – Expands Senior Leadership Team to Accelerate Next Phase of Commercialization

Retrieved on: 
Thursday, November 30, 2023
Medical Devices, Health, AMS, Acquisition, IP, Boston Scientific, Medtronic, Urology, Cleveland Clinic, Male, FDA, Uro, LUTS, Test management, Female, Axon Enterprise, Medical device, Compaq Contura

The Series A funding round includes investment from Laborie and other existing investors in the Company.

Key Points: 
  • The Series A funding round includes investment from Laborie and other existing investors in the Company.
  • Funding will be used to achieve FDA 510(k) clearance of the Glean™ Urodynamics System (Glean) and launch the product in the U.S. in 2024.
  • “Laborie looks forward to leveraging our expertise and leadership in the global urology market to support the Bright Uro team,” said Michael Frazzette, President & CEO of Laborie.
  • Bright Uro Founder and CEO Derek Herrera stated, “I am so proud of our team for achieving this incredible milestone!

Laborie Medical Technologies Invests in Medical Technology Start-Up Bright Uro

Retrieved on: 
Thursday, November 30, 2023
Incontinence, Urine, Woman, Pressure, Lower urinary tract symptoms, Investor AB, Patient, System, Urethra, LUTS, Urinary incontinence, Standard of care, Test management, Urodynamic testing, Management, Urology, Gleaning

PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.

Key Points: 
  • PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.
  • Founded in 2021, Bright Uro is developing the Glean Urodynamic System™, a wireless, catheter-free, urodynamic monitoring system intended to quantify the pressure characteristics of the lower urinary tract.
  • "We're thrilled to be working with Laborie," says Bright Uro Founder & CEO Derek Herrera.
  • "Laborie looks forward to leveraging our expertise and leadership in the global urodynamics market to support the Bright Uro team," said Michael Frazzette, President & CEO of Laborie Medical Technologies.

Olympus Announces Two New Category I CPT Codes for the iTind Procedure

Retrieved on: 
Friday, October 20, 2023
Patient, Ageing, Olympus Corporation, Health care, Medicare, American Medical Association, Physician, LUTS, AMA, Urine, Blood, Urinary tract infection, CPT, Olympus, BPH, UNITE, Centers for Medicare & Medicaid Services, CMS, Health insurance, Medicaid

The release of these two new Category I CPT codes represents a major reimbursement milestone for the iTind procedure that will standardize and streamline the reimbursement process.

Key Points: 
  • The release of these two new Category I CPT codes represents a major reimbursement milestone for the iTind procedure that will standardize and streamline the reimbursement process.
  • CPT codes are granted and maintained by the AMA CPT Editorial Panel and are used by government payers, including Medicare and Medicaid, and commercial health plans to describe healthcare services and procedures for reimbursement.
  • The two new CPT codes for the iTind procedure will go into effect on or after January 1, 2025.
  • Patients who are candidates for the iTind procedure may be assisted in navigating medical insurance systems through the Olympus UNITE program.

Novel iTind Procedure Now Included in Treatment Guideline for Lower Urinary Tract Symptoms Caused by Enlarged Prostate

Retrieved on: 
Thursday, September 28, 2023
Urine, BPH, AUA, LUTS, Urination, Quality of life, Urinary tract infection, American Urological Association, Olympus Corporation, Research, Prostate, National Prostate Health Month, Patient, Physician, Blood, Ageing, Medical imaging

CENTER VALLEY, Pa., Sept. 28, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today that its iTind™ procedure is now included in the American Urological Association (AUA) clinical practice guideline for management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), also known as enlarged prostate. The iTind procedure is reflected in the new procedure category, Temporary Implanted Prostatic Devices (TIPD).i The addition of the TIPD category is based on expert opinion reflecting peer-reviewed treatment recommendations and research updates.

Key Points: 
  • The iTind procedure is reflected in the new procedure category, Temporary Implanted Prostatic Devices (TIPD).i The addition of the TIPD category is based on expert opinion reflecting peer-reviewed treatment recommendations and research updates.
  • The minimally invasive iTind procedure involves the placement of a temporarily implanted nitinol device that reshapes the prostatic urethra without burning or cutting out the prostate.
  • "This guidance reflects compelling clinical evidence and positive clinical experience with the iTind procedure."
  • In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate.

AUA Releases Amendment to the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline

Retrieved on: 
Thursday, September 14, 2023
PAE, Male, Prostatic artery embolization, Prevalence, Guideline, E pluribus unum, Epithelium, AUA, BPH, LUTS, Urethra, Ageing, American Urological Association, Prostate, Literature, MD, Patient, Finasteride, Water, Memorial Sloan Kettering Cancer Center, Diagnosis, Benign prostatic hyperplasia, System, ULR, Update, Medical imaging, Dietary supplement

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.
  • Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the production of smooth muscle and epithelial cells within the prostatic transition zone.
  • The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society.
  • Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023.

MCRA Assists Procept BioRobotics Establish Reimbursement Listing in Japan

Retrieved on: 
Wednesday, September 13, 2023
Medical Affairs Bureau, Partnership, Senior, Biorobotics, BPH, Procept, LUTS, MCRA, Clinical trial, Patient, Physician, Quality assurance, Robotics, Jabberwocky, Medical device, Health insurance, Aquablation therapy, Computer security

In February 2022, Procept BioRobotics achieved regulatory approval for the Aquabeam Robotic System through strategic partnership with Vorpal Technologies K.K.

Key Points: 
  • In February 2022, Procept BioRobotics achieved regulatory approval for the Aquabeam Robotic System through strategic partnership with Vorpal Technologies K.K.
  • Following regulatory approval, Vorpal led the reimbursement consultation and application process to establish a new reimbursement category listing in June 2023, marking Vorpal's third new reimbursement listing this year.
  • Vorpal Technologies' General Manager, Samuel Pollard, said, "We are honored to have Procept BioRobotics trust Vorpal with this important role and proud to have achieved this new category reimbursement listing for the Aquabeam Robotic System.
  • Our team has continued to shine in the reimbursement and regulatory space, helping foreign manufacturers navigate Japan market entry.

NorthShore University HealthSystem offers expanded access to treat most common prostate ailment

Retrieved on: 
Wednesday, August 16, 2023
TURP, University, Anatomy, BPH, Urination, LUTS, Quality of life, Swedish Hospital, Incontinence, Prostate, North, Patient, Standard of care, NorthShore University HealthSystem, Ageing, Erectile dysfunction, FDA, Medical imaging, Nursing, Aquablation therapy, Urology

EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH).

Key Points: 
  • EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH).
  • NorthShore will also install a third AquaBeam system at Swedish Hospital on the north side of Chicago.
  • BPH is the most common prostate ailment, affecting nearly 40 million men in the United States, with more than half of men aged 50 and above impacted by the condition.
  • For more information about NorthShore University HealthSystem’s urological services and to schedule an appointment, visit www.northshore.org/urological-health .